Tin tức & Cập nhật

SWOG 1500: PFS longer with cabozantinib than sunitinib in mPRCC

09 Mar 2021 bởi

Cabozantinib reduces the risk of disease progression or death by 40 percent compared with the current standard sunitinib in patients with metastatic papillary renal cell carcinoma (mPRCC) – a primary malignant tumour of the renal tubular epithelium – in the phase 2 SWOG 1500 study.

SWOG 1500: PFS longer with cabozantinib than sunitinib in mPRCC

09 Mar 2021

Berotralstat reduces HAE attacks regardless of baseline attack rates, prior treatment

09 Mar 2021 bởi

Subgroup analyses of the phase III APeX-2 trial presented at AAAAI 2021 showed that use of the oral plasma kallikrein inhibitor berotralstat led to consistent reductions in attack frequency in patients with hereditary angioedema (HAE), irrespective of baseline attack rates and prior prophylaxis.

Berotralstat reduces HAE attacks regardless of baseline attack rates, prior treatment

09 Mar 2021

First-line infliximab shows promise in children with moderate-to-severe CD

09 Mar 2021

Use of infliximab in the first line setting appears to yield better results than conventional treatment in children with moderate-to-severe Crohn’s disease (CD), facilitating short-term clinical and endoscopic remission and being associated with a greater likelihood of maintaining clinical remission at week 52 on azathioprine monotherapy, according to a study.

First-line infliximab shows promise in children with moderate-to-severe CD

09 Mar 2021

Netarsudil no help in steroid-induced IOP elevation after corneal transplantation

09 Mar 2021

Netarsudil falls short of reducing the risk of steroid-induced elevation of intraocular pressure (IOP) in patients who have received corneal transplant, a study has found.

Netarsudil no help in steroid-induced IOP elevation after corneal transplantation

09 Mar 2021

N-803 shows promise for BCG-unresponsive NMIBC carcinoma in situ

08 Mar 2021 bởi

Intravesical administration of the IL-15RαFc* superagonist N-803 with BCG** demonstrated a strong efficacy and an excellent safety and tolerability profile in patients with BCG-unresponsive high-grade NMIBC*** carcinoma in situ, according to an interim analysis presented at ASCO GU 2021.

N-803 shows promise for BCG-unresponsive NMIBC carcinoma in situ

08 Mar 2021

Intensive lipid-lowering therapy benefits patients with polyvascular disease, too

08 Mar 2021

Intensive lipid-lowering therapy (ILT) helps patients with polyvascular disease as much as it does those with monovascular disease, a study has shown. Furthermore, the ILT-induced benefits in the former are independent of baseline low-density lipoprotein cholesterol (LDL-C) levels.

Intensive lipid-lowering therapy benefits patients with polyvascular disease, too

08 Mar 2021

ATTRACTION-3: Nivolumab significantly improves OS in advanced ESCC

08 Mar 2021 bởi

Treatment with nivolumab led to significantly improved overall survival (OS) in patients with advanced oesophageal squamous cell carcinoma (ESCC), according to updated results of the ATTRACTION-3* study presented at ASCO GI 2021.

ATTRACTION-3: Nivolumab significantly improves OS in advanced ESCC

08 Mar 2021

One-week doxycycline outshines single-dose azithromycin for rectal chlamydia

07 Mar 2021

Patients with rectal chlamydia infection may fare better with a weeklong course of doxycycline than with a single dose of azithromycin, according to a study.

One-week doxycycline outshines single-dose azithromycin for rectal chlamydia

07 Mar 2021

Lenvatinib + pembrolizumab shows CLEAR survival benefit over sunitinib in advanced RCC

06 Mar 2021 bởi

The combination therapy of lenvatinib plus pembrolizumab significantly improves survival outcomes compared with the standard-of-care treatment of sunitinib in the first-line setting for advanced renal cell carcinoma (RCC), according to the CLEAR* study presented at the 2021 ASCO GU Cancer Symposium.

Lenvatinib + pembrolizumab shows CLEAR survival benefit over sunitinib in advanced RCC

06 Mar 2021

Anxiety, fear may promote reliance on chronic opioid analgesic therapy for pain

06 Mar 2021

Among patients with chronic, noncancer pain, fear avoidance beliefs and behaviour play an important role in refractory chronic opioid analgesic therapy reliance, as shown in a study.

Anxiety, fear may promote reliance on chronic opioid analgesic therapy for pain

06 Mar 2021

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

SWOG 1500: PFS longer with cabozantinib than sunitinib in mPRCC

SWOG 1500: PFS longer with cabozantinib than sunitinib in mPRCC

Berotralstat reduces HAE attacks regardless of baseline attack rates, prior treatment

Berotralstat reduces HAE attacks regardless of baseline attack rates, prior treatment

First-line infliximab shows promise in children with moderate-to-severe CD

First-line infliximab shows promise in children with moderate-to-severe CD

Netarsudil no help in steroid-induced IOP elevation after corneal transplantation

Netarsudil no help in steroid-induced IOP elevation after corneal transplantation

N-803 shows promise for BCG-unresponsive NMIBC carcinoma in situ

N-803 shows promise for BCG-unresponsive NMIBC carcinoma in situ

Intensive lipid-lowering therapy benefits patients with polyvascular disease, too

Intensive lipid-lowering therapy benefits patients with polyvascular disease, too

ATTRACTION-3: Nivolumab significantly improves OS in advanced ESCC

ATTRACTION-3: Nivolumab significantly improves OS in advanced ESCC

One-week doxycycline outshines single-dose azithromycin for rectal chlamydia

One-week doxycycline outshines single-dose azithromycin for rectal chlamydia

Lenvatinib + pembrolizumab shows CLEAR survival benefit over sunitinib in advanced RCC

Lenvatinib + pembrolizumab shows CLEAR survival benefit over sunitinib in advanced RCC

Anxiety, fear may promote reliance on chronic opioid analgesic therapy for pain

Anxiety, fear may promote reliance on chronic opioid analgesic therapy for pain